HealthDay on MSN1d
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate Cancer
For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
Investors who Lost Money on ESSA Pharma Inc. (EPIX) Should Contact Levi & Korsinsky about Pending Class Action - EPIX
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn ...
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA Pharma
If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...
Targeted Oncology8d
Talazoparib Plus Enzalutamide Extends Survival in mCRPC
Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...
Class Action Filed Against ESSA Pharma Inc. (EPIX) Seeking Recovery For Investors – Contact The Gross Law Firm
Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required ...
Morningstar17d
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against ESSA Pharma Inc. and Certain Officers - EPIX
Phase 2 of the M-E Combination Study compared this recommended combination dose with a 160 mg QD enzalutamide monotherapy—the standard of care for the intended patient population. The primary ...